| There is a correlation between the occurrence of adverse events and outcomes for patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. |
| This understanding is crucial for further enhancing our daily clinical practice and providing patients with hepatocellular carcinoma with the best possible management of the currently available therapeutic strategies. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.